Anna Neustaeter1,2,3, Ilja Nolte2, Harold Snieder2,3, Nomdo M Jansonius4,5. 1. Department of Ophthalmology, University of Groningen, University Medical Center Groningen, P.O.Box 30.001, 9700 RB, Groningen, Netherlands. 2. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Graduate School of Medical Sciences (Research School of Behavioural and Cognitive Neurosciences), University of Groningen, Groningen, The Netherlands. 4. Department of Ophthalmology, University of Groningen, University Medical Center Groningen, P.O.Box 30.001, 9700 RB, Groningen, Netherlands. n.m.jansonius@umcg.nl. 5. Graduate School of Medical Sciences (Research School of Behavioural and Cognitive Neurosciences), University of Groningen, Groningen, The Netherlands. n.m.jansonius@umcg.nl.
Abstract
BACKGROUND: Early detection of glaucoma is paramount to maintain patients' eyesight, however glaucomatous vision loss tends to begin in the periphery with up to 50% of patients unaware they are affected. Because glaucomatous vision loss is permanent, screening appears attractive, but currently is not cost-effective. Therefore we aim to investigate the utility of genetic pre-screening for glaucoma in a population-based setting, called EyeLife. METHODS: EyeLife adopts a double blind prospective design with contrasting groups. Selected participants (n = 1600) from the Lifelines cohort are 55 years of age or older, and of either the highest or lowest 20% of the genetic risk distribution for glaucoma. We obtained a highly curated list of genetic variants from the literature to obtain each participants' genetic risk for glaucoma. Participants will undergo comprehensive ophthalmic screening. The primary outcome is the relative risk of glaucoma given a high genetic risk compared to a low genetic risk. DISCUSSION: If genetic pre-screening is successful, it will increase the yield of a glaucoma screening program by focusing on high-risk individuals. This, in turn, may improve long-term visual health of middle-aged and elderly people. TRIAL REGISTRATION: Ethics approval was obtained on January 31, 2019, and the study was retrospectively registered with the Netherlands Trial Register ( NL8718 ) on the 17th of June, 2020.
BACKGROUND: Early detection of glaucoma is paramount to maintain patients' eyesight, however glaucomatous vision loss tends to begin in the periphery with up to 50% of patients unaware they are affected. Because glaucomatous vision loss is permanent, screening appears attractive, but currently is not cost-effective. Therefore we aim to investigate the utility of genetic pre-screening for glaucoma in a population-based setting, called EyeLife. METHODS: EyeLife adopts a double blind prospective design with contrasting groups. Selected participants (n = 1600) from the Lifelines cohort are 55 years of age or older, and of either the highest or lowest 20% of the genetic risk distribution for glaucoma. We obtained a highly curated list of genetic variants from the literature to obtain each participants' genetic risk for glaucoma. Participants will undergo comprehensive ophthalmic screening. The primary outcome is the relative risk of glaucoma given a high genetic risk compared to a low genetic risk. DISCUSSION: If genetic pre-screening is successful, it will increase the yield of a glaucoma screening program by focusing on high-risk individuals. This, in turn, may improve long-term visual health of middle-aged and elderly people. TRIAL REGISTRATION: Ethics approval was obtained on January 31, 2019, and the study was retrospectively registered with the Netherlands Trial Register ( NL8718 ) on the 17th of June, 2020.
Authors: Michael W Marcus; Margriet M de Vries; Francisco G Junoy Montolio; Nomdo M Jansonius Journal: Ophthalmology Date: 2011-10 Impact factor: 12.079
Authors: M F Armaly; D E Krueger; L Maunder; B Becker; J Hetherington; A E Kolker; R Z Levene; A E Maumenee; I P Pollack; R N Shaffer Journal: Arch Ophthalmol Date: 1980-12
Authors: Henriët Springelkamp; Adriana I Iglesias; Aniket Mishra; René Höhn; Robert Wojciechowski; Anthony P Khawaja; Abhishek Nag; Ya Xing Wang; Jie Jin Wang; Gabriel Cuellar-Partida; Jane Gibson; Jessica N Cooke Bailey; Eranga N Vithana; Puya Gharahkhani; Thibaud Boutin; Wishal D Ramdas; Tanja Zeller; Robert N Luben; Ekaterina Yonova-Doing; Ananth C Viswanathan; Seyhan Yazar; Angela J Cree; Jonathan L Haines; Jia Yu Koh; Emmanuelle Souzeau; James F Wilson; Najaf Amin; Christian Müller; Cristina Venturini; Lisa S Kearns; Jae Hee Kang; Yih Chung Tham; Tiger Zhou; Elisabeth M van Leeuwen; Stefan Nickels; Paul Sanfilippo; Jiemin Liao; Herma van der Linde; Wanting Zhao; Leonieke M E van Koolwijk; Li Zheng; Fernando Rivadeneira; Mani Baskaran; Sven J van der Lee; Shamira Perera; Paulus T V M de Jong; Ben A Oostra; André G Uitterlinden; Qiao Fan; Albert Hofman; E-Shyong Tai; Johannes R Vingerling; Xueling Sim; Roger C W Wolfs; Yik Ying Teo; Hans G Lemij; Chiea Chuen Khor; Rob Willemsen; Karl J Lackner; Tin Aung; Nomdo M Jansonius; Grant Montgomery; Philipp S Wild; Terri L Young; Kathryn P Burdon; Pirro G Hysi; Louis R Pasquale; Tien Yin Wong; Caroline C W Klaver; Alex W Hewitt; Jost B Jonas; Paul Mitchell; Andrew J Lotery; Paul J Foster; Veronique Vitart; Norbert Pfeiffer; Jamie E Craig; David A Mackey; Christopher J Hammond; Janey L Wiggs; Ching-Yu Cheng; Cornelia M van Duijn; Stuart MacGregor Journal: Hum Mol Genet Date: 2017-01-15 Impact factor: 6.150
Authors: Priya Gupta; Di Zhao; Eliseo Guallar; Fang Ko; Michael V Boland; David S Friedman Journal: Invest Ophthalmol Vis Sci Date: 2016-05-01 Impact factor: 4.799